There are currently 120 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Autism participants are California, Ohio, New York and Pennsylvania.
Sacituzumab Govitecan in Recurrent Glioblastoma
NCT04559230
Recruiting
This is an open-label single arm study. All patients will receive the investigational agent.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio +2 locations
Conditions: Glioblastoma
Register for Updates
Surgical Study on Upfront or Recurrent High-Grade Glioma (WHO Grade III and IV) Electrical Activity
NCT05565118
Recruiting
The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: High Grade Glioma, Glioblastoma
Register for Updates
Methimazole in Patients With Progressive Glioblastoma
NCT05607407
Recruiting
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Glioma
Register for Updates
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071
Recruiting
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
04/27/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +126 locations
Conditions: Anaplastic Astrocytoma, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, Anaplastic Astrocytoma, Not Otherwise Specified
Register for Updates
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
NCT03970447
Recruiting
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +60 locations
Conditions: Glioblastoma
Register for Updates
Neoadjuvant Chemoradiation for Resectable Glioblastoma
NCT04209790
Recruiting
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This Phase II study design would be used to proceed with the study treatment after meeting pre-specified events in the initial phase, with goal being to determine whether the new treatment paradigm is suf... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
04/26/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: Glioblastoma, Surgery, High Grade Glioma
Register for Updates
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065
Recruiting
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response c... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
04/26/2024
Locations: University of California, San Francisco, San Francisco, California +2 locations
Conditions: Diffuse Midline Glioma (DMG), Glioblastoma, Recurrent Ependymoma, Spinal Cord Glioma, Recurrent Malignant Central Nervous System Neoplasm, CNS Tumor, Central Nervous System Tumor, World Health Organization (WHO) Grade III Glioma
Register for Updates
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT02611024
Recruiting
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Sarcoma Oncology Center, Santa Monica, California +21 locations
Conditions: Advanced Solid Tumors, Glioblastoma, Endometrial Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Soft Tissue Sarcoma (Excluding GIST), Epithelial Ovarian Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
Register for Updates
A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma
NCT05187624
Recruiting
This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: UCLA Neuro-Oncology Program, Los Angeles, California +11 locations
Conditions: Glioblastoma
Register for Updates
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
NCT04216329
Recruiting
Background: Glioblastoma is a type of brain cancer. Treatments include radiation, chemotherapy, and surgery. But survival rates are poor. Researchers think that the drug selinexor, when combined with chemotherapy and radiation, might help. Objective: To learn the highest dose of selinexor that people with brain cancer can tolerate when given with temozolomide and radiation therapy. Eligibility: People ages 18 and older with brain cancer that has not been treated with chemotherapy or radiati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Gliosarcoma, Newly Diagnosed, Glioblastoma
Register for Updates
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
NCT03718767
Recruiting
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes IDH1 or IDH2. If there are a high number of mutations in a tumor, it is called hypermutator phenotype (HMP). The drug nivolumab helps the immune system fight cancer. Researchers think it can be more effective in patients with IDH1 or IDH2 mutated gliomas with HMP. They will test gliomas with and without HMP. Objectives: To see if nivolumab stops tumor growth and prolongs the time... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma, Glioblastoma, High Grage Glioma, Low Grade Glioma, Malignant Glioma
Register for Updates
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169
Recruiting
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Northwestern University, Chicago, Illinois +12 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Register for Updates